About me
Jeb Keiper, MS, MBA, is CEO and president of Nimbus Therapeutics, LLC, a Boston-based biotechnology company focused on developing breakthrough medicines for patients through precision small molecule design. Jeb has overseen the discovery and development of multiple programs into clinical testing across a range of indications, raised >$400M in equity funding, and executed deals worth >$7B and the return of >$4B in gains back to equity holders. Most notably, in 2016, Gilead acquired Nimbus’ NASH program for $1.2B, and in 2023, Takeda acquired Nimbus’ TYK2 program for psoriasis for $4B, one of the largest drug acquisitions that year.
Before Nimbus, Jeb was VP of business development at GSK Oncology where he led critical collaborations including the Novartis-GSK oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, he was a consultant at McKinsey & Company after having started his career as a pharmaceutical chemist at Pfizer.
